BioSpace News Archive

Q32 Bio Inc., a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, and Homology Medicines, Inc., announced they have entered into a definitive merger agreement to combine the companies in an all-stock transaction.

AbbVie (NYSE: ABBV) today announced detailed results published in The Lancet evaluating the efficacy, safety, and tolerability of UBRELVY® (ubrogepant) 100 mg for the acute treatment of migraine when administered during the prodrome of a migraine attack.

Avantor, Inc. announced that President and CEO Michael Stubblefield , will be participating in a fireside chat at the Evercore ISI HealthCONx Conference in Miami, Florida on Tuesday, November 28, at 10:00 a.m. Eastern Standard Time.

Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, announced that it will regain full development and commercial rights to bempikibart from Amgen.

Claris GenomiX, Inc. announced today that ColoType, its patented mRNA-based cancer diagnostic, is available for exclusive licensing.

ACROBiosystems recently announces the launch of GMP grade DLL4. GMP grade DLL4 is a recombinant, soluble form of Delta-like Ligand 4, or DLL4, that is one of the few products available on the market manufactured under GMP conditions.

Zimmer Biomet Holdings, Inc. today announced that members of the Zimmer Biomet management team will be presenting at the 2023 Piper Sandler Healthcare Conference on Thursday, November 30, 2023 , at 9:00 a.m. ET (6:00 a.m. PT ).

Ad Astra Diagnostics today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its QScout™ rapid-result hematology system, which provides fast, point-of-care white blood cell counts (WBCs), neutrophil-to-lymphocyte ratio, and differentiates the number and percent of five types of mature WBCs as well as immature granulocytes.

Delpor, Inc. (Delpor), a clinical stage biopharmaceutical company that utilizes innovative technologies to develop once-yearly therapeutics for chronic conditions, today announced topline results of its DLP-114 Phase 1b/2a clinical study during which schizophrenia patients received treatment for up to one year after a single administration.

Embr Labs, Inc today announced the formal appointment of Dr. Maria Sophocles as Embr Labs’ Chief Medical Officer.